Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations

BACKGROUND: Inherited CDKN2A mutation is a strong risk factor for cutaneous melanoma. Moreover, carriers have been found to have poor melanoma-specific survival. In this study, responses to novel immunotherapy agents in CDKN2A mutation carriers with metastatic melanoma were evaluated. METHODS: CDKN2...

Descripción completa

Detalles Bibliográficos
Autores principales: Helgadottir, Hildur, Ghiorzo, Paola, van Doorn, Remco, Puig, Susana, Levin, Max, Kefford, Richard, Lauss, Martin, Queirolo, Paola, Pastorino, Lorenza, Kapiteijn, Ellen, Potrony, Miriam, Carrera, Cristina, Olsson, Håkan, Höiom, Veronica, Jönsson, Göran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Cancer Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231460/
https://www.ncbi.nlm.nih.gov/pubmed/30291219
http://dx.doi.org/10.1136/jmedgenet-2018-105610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231460/
https://www.ncbi.nlm.nih.gov/pubmed/30291219
http://dx.doi.org/10.1136/jmedgenet-2018-105610

Ejemplares similares